Market News & Trends
Fusion Antibodies Partners With Eurofins Discovery to Support Innovative Preclinical Drug Discovery Research
Fusion Antibodies plc recently announced it has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE (EUFI.PA) group company; a leading provider of products and services to the….
Adhera Therapeutics Signs Exclusive License Agreement With Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate
Adhera Therapeutics, Inc. recently announced it has executed an exclusive license agreement with Melior Pharmaceuticals I, Inc. defining the terms and conditions for which Adhera will license MLR-1023….
Poseida Therapeutics Announces FDA Clearance of IND Application for Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics, Inc. recently announced the US FDA has cleared its Investigational New Drug (IND) application for P-BCMA-ALLO1, the company's first fully allogeneic CAR-T product…
Nuvectis Pharma Raises $15 Million & In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor From the CRT Pioneer Fund
Nuvectis Pharma, Inc. recently announced the completion of a $15-million Series A Preferred Stock financing with institutional and private investors. Nuvectis also announced that it…
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA’s Pulmonology, Allergy & Critical Care Division
Diffusion Pharmaceuticals Inc. recently announced it has obtained clearance of its Investigational New Drug (IND) application submitted to the US FDA Pulmonology, Allergy, and Critical…
Aerami Therapeutics Announces Orphan Drug Designation for Imatinib for the Treatment of Pulmonary Arterial Hypertension
Aerami Therapeutics, Inc. recently announced the US FDA has granted the company orphan drug designation for imatinib for treatment of patients with pulmonary arterial hypertension…
Quantum Genomics Presents Results From Phase 2b QUORUM Study of Firibastat in Heart Failure
Quantum Genomics recently announced results of the Phase 2b QUORUM study were presented by Prof. Gilles Montalescot (Paris) on August 27, 2021 during the 2021…
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
AC Immune SA recently announced Genentech, a member of the Roche Group, has informed the company that Lauriet, a placebo-controlled Phase 2 study evaluating the…
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
Quotient Sciences, the drug development and manufacturing accelerator, recently announced a £6.3 million-pound investment in its recently acquired manufacturing facility in Alnwick, UK…..
Mitsubishi Chemical Advanced Materials to Become Climate Neutral by 2023 & Targets Climate Positivity by 2030
Mitsubishi Chemical Advanced Materials AG (MCAM), a leading global manufacturer of high-performance materials, is proud to announce its goal to achieve climate positivity in its…
Aptamer Group & Bio-Works Technologies Partner to Enable Improved Solutions for Gene Therapy Manufacturing
Aptamer Group Ltd and Bio-Works Technologies AB recently announced they have entered into an agreement to co-develop a new affinity resin for improved purification and scale up of….
Noxopharm Phase 1 Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda®), a TBK1 (TANK-binding kinase 1) inhibitor,…
BioPlx Announces Focus on Developing Cure for Antibiotic-Resistant Bacteria
Antimicrobial Resistance (AMR) is one of the greatest threats to society, human and animal health, and economic prosperity. Those are the unequivocal words regarding the…
Recipharm Launches New Laboratory to Expand Analytical Services Offering
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced the completion of a new analytical laboratory at its facility in Bengaluru, India. The new…
Shape Therapeutics Enters Strategic Research Collaboration With Roche to Advance Breakthrough AAV-Based RNA Editing Technology for Neuroscience & Rare Disease Indications
Through this partnership Shape will apply its proprietary RNA editing platform RNAfix and potentially leverage its AAVid technology platform for next-generation tissue-specific adeno-associated viruses (AAVs) for the development of gene therapy for….
Vifor Pharma & Cara Therapeutics Announce US FDA Approval of Injection for Treating Moderate-to-Severe Pruritus in Hemodialysis Patients
Cara Therapeutics and Vifor Pharma recently announced the US FDA has approved KORSUVA (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with….
SomaLogic & Twist Bioscience Corporation Announce Partnership to Discover Novel Therapeutic Targets & Antibodies
CM Life Sciences II and SomaLogic, Inc., and Twist Bioscience Corporation recently announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on….
Vyant Bio & Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
Vyant Bio, Inc. and Cyclica, Inc. recently announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s….
Junshi & Coherus Biosciences Announce Positive Interim Results of CHOICE-01 Phase 3 Clinical Trial
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. recently announced positive interim results from the pivotal study CHOICE-01 (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating….
Persica Pharmaceuticals Has Completed the First Stage of its Clinical Trial on Unique Injectable to Treat Chronic Lower Back Pain
Persica Pharmaceuticals Ltd recently announced it has successfully completed the first stage of a Phase Ib clinical trial to evaluate the safety, tolerability, and pharmacokinetics…
